REGENERON PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax
REGENERON PHARMACEUTICALS, INC. (REGN) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-05.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax · last filed 2024-02-05
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for the quarter ending 2023-12-31 was $0.00.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for the quarter ending 2023-09-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for the quarter ending 2023-06-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for fiscal 2022 was $1.00M, a 11.11% increase from fiscal 2021.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for fiscal 2021 was $900.00K.
- REGENERON PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification and tax for fiscal 2020 was -$900.00K.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | $0.00 derived: sum of 2 quarters · filed 2024-02-05 | $0.00 derived: sum of 3 quarters · filed 2024-02-05 | $0.00 10-K · filed 2024-02-05 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | $0.00 derived: sum of 4 quarters · filed 2024-02-05 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | $0.00 derived: sum of 3 quarters · filed 2024-02-05 | $0.00 derived: sum of 4 quarters · filed 2024-02-05 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | $0.00 derived: sum of 2 quarters · filed 2024-02-05 | $0.00 derived: sum of 3 quarters · filed 2024-02-05 | $0.00 derived: sum of 4 quarters · filed 2024-02-05 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | $0.00 derived: sum of 2 quarters · filed 2024-02-05 | $0.00 derived: sum of 3 quarters · filed 2024-02-05 | $1.00M 10-K · filed 2024-02-05 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $1.00M 10-Q · filed 2023-11-02 | $1.20M derived: sum of 4 quarters · filed 2024-02-05 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-03 | $1.00M 10-Q · filed 2023-08-03 | $1.20M derived: sum of 3 quarters · filed 2024-02-05 | $1.40M derived: sum of 4 quarters · filed 2024-02-05 |
| 2022-03-31 | $1.00M 10-Q · filed 2023-05-04 | $1.20M derived: sum of 2 quarters · filed 2024-02-05 | $1.40M derived: sum of 3 quarters · filed 2024-02-05 | $1.70M derived: sum of 4 quarters · filed 2024-02-05 |
| 2021-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | $400.00K derived: sum of 2 quarters · filed 2024-02-05 | $700.00K derived: sum of 3 quarters · filed 2024-02-05 | $900.00K 10-K · filed 2024-02-05 |
| 2021-09-30 | $200.00K 10-Q · filed 2022-11-03 | $500.00K derived: sum of 2 quarters · filed 2022-11-03 | $700.00K 10-Q · filed 2022-11-03 | $1.00M derived: sum of 4 quarters · filed 2023-02-06 |
| 2021-06-30 | $300.00K 10-Q · filed 2022-08-03 | $500.00K 10-Q · filed 2022-08-03 | $800.00K derived: sum of 3 quarters · filed 2023-02-06 | $1.00M derived: sum of 4 quarters · filed 2023-02-06 |
| 2021-03-31 | $200.00K 10-Q · filed 2022-05-04 | $500.00K derived: sum of 2 quarters · filed 2023-02-06 | $700.00K derived: sum of 3 quarters · filed 2023-02-06 | $700.00K derived: sum of 4 quarters · filed 2023-02-06 |
| 2020-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | $500.00K derived: sum of 2 quarters · filed 2023-02-06 | $500.00K derived: sum of 3 quarters · filed 2023-02-06 | -$900.00K 10-K · filed 2023-02-06 |
| 2020-09-30 | $200.00K 10-Q · filed 2021-11-04 | $200.00K derived: sum of 2 quarters · filed 2021-11-04 | -$1.20M 10-Q · filed 2021-11-04 | -$1.00M derived: sum of 4 quarters · filed 2022-02-07 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 | -$1.40M 10-Q · filed 2021-08-05 | -$1.20M derived: sum of 3 quarters · filed 2022-02-07 | -$1.50M derived: sum of 4 quarters · filed 2022-02-07 |
| 2020-03-31 | -$1.40M 10-Q · filed 2021-05-06 | -$1.20M derived: sum of 2 quarters · filed 2022-02-07 | -$1.50M derived: sum of 3 quarters · filed 2022-02-07 | -$2.90M derived: sum of 4 quarters · filed 2022-02-07 |
| 2019-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-07 | -$100.00K derived: sum of 2 quarters · filed 2022-02-07 | -$1.50M derived: sum of 3 quarters · filed 2022-02-07 | -$2.50M 10-K · filed 2022-02-07 |
| 2019-09-30 | -$300.00K 10-Q · filed 2020-11-05 | -$1.70M derived: sum of 2 quarters · filed 2020-11-05 | -$2.70M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$1.40M 10-Q · filed 2020-08-05 | -$2.40M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | -$1.00M 10-Q · filed 2020-05-05 | |||
| 2018-12-31 | $700.00K 10-K · filed 2021-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |